A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplat recipients: 10,000/μL versus 20,000/μL trigger

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 10, 2002, Pages 569-576

  Zumberg, Marc S ^a   Del Rosario, Maria Luz U ^a   Nejame, Christine F ^a   Pollock, Brad H ^a   Garzarella, Linda ^a   Kao, K J ^a   Lottenberg, Richard ^a   Wingard, John R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bleeding; Platelet transfusion threshold; Stem cell transplant; Trigger

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B; CYCLOPHOSPHAMIDE;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; BLEEDING DISORDER; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SAFETY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS PREVENTION; WHOLE BODY RADIATION;

EID: 0036433219     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12434952     Document Type: Article

References (24)

1. Gaydos LA, Freirich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905-909.
2. Han T, Stutzman L, Cohen E, Kum U. Effect of platelet transfusion on hemorrhage in patients with acute leukemia. An autopsy study. Cancer. 1996;19:1937-1942.
3. Chang HY, Rodriguez V, Narboni G, et al. Causes of death in adults with acute leukemia. Medicine. 1976;55:259-268.
4. Piscion PT, Banson Y, Hume H, et al. Prophylactic versus therapeutic platelet transfusion practice in hematology and/or oncology patients. Transfusion. 1995;35:498-502.
5. Wallace EL, Churchhill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion. 1995;35:802-812.
6. Gmur J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet. 1991;338:1223-1226.
7. Beutler E. Platelet transfusions: the 20,000/μL trigger. Blood. 1993;81:1411-1413.
8. Menitove JE, Snyder EL. Platelet transfusion practice: time for renewed consensus. Transfusion. 1998;38:707-709.
9. Contreras M. Final statement from the consensus conference on platelet transfusion. Transfusion. 1998;38:796-797.
10. Norfolk DR, Ancliffe PJ, Contreras M, et al. Consensus conference on platelet transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Br J Haematol. 1998;101:609-617.
11. Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL. J Clin Oncol. 1997;15:1143-1149.
12. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997;337:1870-1875.
13. 9/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91: 3601-3606.
14. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, et al. Clinical result of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant. 1996;18:931-935.
15. Rinder HM. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol. 1999;6:437-441.
16. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood. 1998;71:383-387.
17. Slichter SJ, Harker L. Thrombocytopenia: mechanism and management of defects in platelet production. Clin Haematol. 1978;7: 523-526.
18. Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: utilization and associated costs in tertiary care hospital. Am J Hematol. 2000;64:251-256.
19. Bernstein SH, Nademanee AP, Vose JM, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood. 1998;91:3509-3517.
20. Weiner RS, Kao KJ. Clinical and laboratory diagnosis of the refractory state. In: Kurtz SR, Brubaker DB, eds. Clinical Decisions in Platelet Therapy. Bethesda, MD: AABB; 1992:74-85.
21. Benson K, Fields K, Hiemenz J, et al. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding. Semin Oncol. 1993;20(suppl 6):102-109.
22. Nevo S, Swan V, Enger C, et al. Acute bleeding after bone marrow transplantation (BMT)-incidence and effect on survival. A quantitative analysis in 1,402 patients. Blood. 1998;91:1469-1477.
23. Hanson SR, Slichter SH. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985;66:1105-1109.
24. Kao KJ, del Rosario MLU. Determination of the rate of reduction in platelet counts in recipients of hematopoetic stem and progenitor cell transplant: clinical implications for platelet transfusion therapy. Transfusion. 1997;37:1163-1168.